Adaptive Biotechnologies Corp vs KB Financial Group, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while KB Financial Group, Inc. trades at $117.53 (market cap $41.21B). The key difference: KB Financial Group, Inc. is far larger — about 10.2× Adaptive Biotechnologies Corp's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KB | |
|---|---|---|
Market Cap | $4.04B | $41.21B |
Sector | Health | Financials |
52-Week High | $25.45 | $124.01 |
52-Week Low | $12.30 | $77.50 |
Enterprise Value | $4.10B | — |
Dividend Yield | — | 2.67% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →